Skip to main content

Table 1 Patients characteristics

From: Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice

  N° (%)
386
Age (years)
 Median 68
 Range 21–88
 Elderly (≥ 70) 170 (44)
Sex
 Male 260 (67.4)
 Female 126 (32.6)
ECOG PS
 0–1 338 (87.6)
 ≥ 2 48 (12.4)
Primary tumor
 NSCLC 156 (40.4)
 Melanoma 163 (42.2)
 Renal cell carcinoma 59 (15.3)
 Others 8 (2.1)
No. of metastatic sites
 ≤ 2 219 (56.7)
 > 2 167 (43.3)
Type of anti-PD-1/PD-L1 agent
 Pembrolizumab 120 (31.1)
 Nivolumab 253 (65.5)
 Atezolizumab 10 (2.6)
 Others 3 (0.8)
Treatment line of immunotherapy
 First 137 (35.5)
 Non-first 249 (64.5)